Screener
Supernus Pharmaceuticals SUPN Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $184,869 | $128,448 |
| Marketable securities | 199,372 | 180,222 |
| Accounts receivable, net | 182,183 | 187,802 |
| Inventories, net | 87,062 | 82,385 |
| Prepaid expenses and other current assets | 78,094 | 65,325 |
| Total current assets | 731,580 | 644,182 |
| Restricted cash | 1,450 | 1,450 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's accounts receivable?
- Supernus Pharmaceuticals (SUPN) reported accounts receivable of $182.18M in Q1 2026.
- How has Supernus Pharmaceuticals's accounts receivable changed year-over-year?
- Supernus Pharmaceuticals's accounts receivable increased by 25.1% year-over-year, from $145.64M to $182.18M.
- What is the long-term trend for Supernus Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accounts receivable has grown at a 5.9% compound annual growth rate (CAGR), from $140.88M to $187.8M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Supernus Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude